Preview: Outpatient Networks a New Reality for Hospitals

Cost factors drive collaboration with clinics and doctor groups.

mPulse Raises $11 Million in Series B Funding

mPulse Mobile has closed an $11 million Series B funding round, bringing its total amount of raised capital to more than $25 million.

Second Sight Announces $10 Million Private Placement

Second Sight Medical Products Inc. in Sylmar announced Monday that it had entered into a $10 million stock purchase agreement with entities owned by the company’s Chairman Gregg Williams

Henry Mayo Hospital Forms Care Network

Henry Mayo Newhall Hospital in Valencia has launched its own clinically integrated network, or CIN, a collection of physicians and clinics that coordinate patient care with the objective of improving customer satisfaction and lowering costs.

MannKind Stock Jumps on FDA News

The stock of MannKind Corp. jumped on Wednesday following news that the Food and Drug Administration would no longer require the company to adhere to a special plan to communicate the risks and benefits of its inhalable insulin Afrezza.

Amgen Starts Year With Strong Earnings

Amgen Inc. beat Wall Street expectations for earnings and revenue in its first fiscal quarter.

Study: Amgen’s Aimovig Curtails Migraine Days

Amgen Inc. said a new study showed its drug Aimovig is an effective preventive treatment migraine patients who have tried other treatments that either didn’t work or had intolerable side effects, the company announced Tuesday.

Preview: New Faces for Older Execs

Skin treatments provide youthful edge for older job-seekers and executives.

Quarterly Results Lift Simulations Plus

Shares of Simulations Plus Inc. rose more than 6 percent Tuesday after the company reported results for its second fiscal quarter.

Amgen to Build High-Tech Plant in Rhode Island

Amgen Inc. will build a new manufacturing plant at the site of its existing facilities in West Greenwich, R.I., the pharma company announced Tuesday.

MannKind Drops 25 Percent on Stock Offering

Shares of MannKind Corp. fell nearly 25 percent Friday, after the company announced a $28 million stock offering.

European Label Expanded for Amgen’s Xgeva

Amgen Inc.’s bone drug Xgeva has been approved by the European Commission for the prevention of skeletal complications in patients with multiple myeloma, a bone marrow cancer.

ApolloMed Merger Complicates Annual Report

Apollo Medical Holdings Inc. has announced its fiscal year results, but the financial numbers only reflect 23 days’ of the company’s performance.

Amgen Drug Approved for Patients with High Risk of Leukemia Relapse

Amgen Inc.’s leukemia drug Blincyto has become the first drug to be approved by the Food and Drug Administration for use in a subgroup of leukemia patients who are at a high risk of relapse following initial treatment.

Sienna Biopharmaceuticals Hires Chief Commercial Officer

Sienna Biopharmaceuticals Inc., an aesthetic dermatological product company based in Westlake Village, has hired Allergan Inc. senior marketing manager Caroline Van Hove as its chief commercial officer.